The MarketWatch News Department was not involved in the creation of this content. -- Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular ...
– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results